Moderna, Inc.

🇺🇸NASDAQ Global Select

Articles

60
Show Summary
Show Bulletpoints
Detailed View
Neutral 0

Moderna lines up 3 investor conference webcasts in May 2026 - Stock Titan

⚠ Source website stocktitan.net is currently unreachable due to technical errors.

🌐 Connection timeouts and network issues block access to the article page.

👋 No content about Moderna's May 2026 investor conference webcasts was found.

⚠️ The source website (stocktitan.net) is currently unreachable, preventing access to the reported news about Moderna's upcoming investor conference webcasts.

🌐 Technical errors indicate a connection timeout and potential network configuration issues for users attempting to load the article page.

📡 Users are advised to check internet connections, proxy settings, and firewall configurations to resolve the ERR_CONNECTION_TIMED_OUT error.

👋 No substantive content regarding Moderna's May 2026 investor presentations could be retrieved from the broken link.

Risk Factors
  • Website failed to load with timeout.
  • Access blocked prevents extracting news.
Risk Factors
  • The website hosting the article failed to load with a connection timed out error, indicating potential reliability issues accessing financial information.
  • Technical difficulties preventing access to the content make it impossible to extract substantive news or analysis about Moderna.
Somewhat Bullish +50

Moderna's Quarterly Earnings Preview: What You Need to Know - Yahoo Finance

📈 Moderna reports Q1 2026 earnings before Friday, May 1 market open.

💸 Analysts expect $2.27 loss, improving 9.9% from prior year's quarter.

📉 Stock surged 117.4% over 52 weeks, outperforming S&P 500 and health care ETF.

⚖ Patent settlement paid up to $2.25 billion eliminates legal overhangs.

💉 European agency approves combination flu and COVID-19 vaccine for those 50+.

📈 Moderna (MRNA) is valued at $21.2 billion and is set to report Q1 2026 earnings before the market opens on Friday, May 1.

💸 Analysts expect a loss of $2.27 per share, representing a 9.9% improvement from the $2.52 loss in the prior year's quarter.

📉 Despite the expected quarterly loss, the company has beaten bottom-line estimates for each of the last four quarters.

💰 For the current fiscal year ending in December, analysts project a loss of $6.99 per share, which is 3.7% narrower than the previous year's loss.

📉 Losses are expected to further decline by 37.9% year-over-year to $4.34 per share in fiscal 2027.

🚀 The stock has surged 117.4% over the past 52 weeks, outperforming both the S&P 500 and the Health Care Select Sector ETF.

⚖️ A patent dispute resolution on Mar. 4 saw shares soar 16% after Moderna agreed to pay up to $2.25 billion to Arbutus Biopharma Corporation.

🏛️ The settlement eliminated legal overhangs, confirmed no future royalties will be required, and clarified the company's infectious disease portfolio.

💉 Moderna received a favorable opinion from the European Medicines Agency for its combination vaccine targeting influenza and COVID-19 in individuals aged 50+.

⚠️ Wall Street analysts currently hold an overall "Hold" rating on MRNA stock with mixed recommendations across buy and sell sides.

🎯 The company trades above the mean analyst price target of $44.90 but below a high potential upside of 151.3% to the street-high target of $135.

Bullish Signals
  • Moderna topped bottom-line estimates for four consecutive quarters.
  • Q4 2025 loss beat consensus by 18.9%.
  • Current fiscal year loss narrowed 3.7% to $6.99 per share.
  • Loss projected to decline 37.9% to $4.34 per share in fiscal 2027.
  • Shares surged 117.4% over the past 52 weeks, outperforming benchmarks.
  • Stock gained 16% after resolving patent dispute for up to $2.25B.
  • Settlement eliminates future royalties for broader infectious disease portfolio.
  • EMA approved combination vaccine for influenza and COVID-19 in ages 50+.
  • Wall Street analysts price target $135, suggesting 151.3% upside potential.
Risk Factors
  • Analysts expect Moderna's Q1 2026 loss of $2.27 per share.
  • No profitability expected for fiscal year ending December 2026.
  • Stock surged 117.4% but analysts maintain a "Hold" rating.
  • Only two analysts recommend strong buy; others suggest sell.
  • $2.25 billion paid to Arbutus and Genevant for disputes.
  • Trading above mean target of $44.90 limits upside potential.
Bullish Signals
  • Moderna has topped Wall Street's bottom-line estimates in each of the last four quarters, demonstrating consistent performance above analyst expectations.
  • In Q4 2025, Moderna's loss of $2.11 per share outpaced consensus expectations by a notable margin of 18.9%.
  • The expected loss for the current fiscal year is $6.99 per share, which is 3.7% narrower than the loss of $7.26 per share in fiscal 2025.
  • Analysts project the loss will further decline 37.9% year-over-year to $4.34 per share in fiscal 2027.
  • Shares skyrocketed 117.4% over the past 52 weeks, significantly outperforming both the S&P 500 Index's 34.9% return and the State Street Health Care Select Sector SPDR ETF's 9.8% uptick.
  • On Mar. 4, shares soared 16% after Moderna resolved a patent dispute and agreed to pay up to $2.25 billion to Arbutus Biopharma Corporation and Genevant Sciences, eliminating a significant legal and financial overhang.
  • The settlement confirmed no future royalties will be required for Moderna's broader infectious disease portfolio.
  • Moderna received a favorable opinion from the European Medicines Agency for its combination vaccine targeting both influenza and COVID-19 in individuals aged 50 and above.
  • Wall Street analysts suggest a Street-high price target of $135, indicating 151.3% potential upside from current trading levels while the company trades above its mean price target of $44.90.
Risk Factors
  • Analysts expect Moderna to report a significant loss of $2.27 per share for the fiscal Q1 2026, representing only a slight improvement from the prior year's loss of $2.52.
  • The company is expected to post a total annual loss of $6.99 per share for the current fiscal year ending in December, with no expectation of profitability in the near term.
  • Despite a massive 117.4% stock price surge over the past 52 weeks, Wall Street analysts maintain an overall "Hold" rating on MRNA's stock.
  • Out of 24 analysts covering the stock, only two recommend "Strong Buy," while one suggests a "Moderate Buy" and two advise a "Strong Sell."
  • The company has paid up to $2.25 billion to Arbutus Biopharma Corporation and Genevant Sciences for patent disputes, creating a substantial cash outflow.
  • Moderna is currently trading above the mean price target of $44.90, suggesting limited upside potential compared to the Street-high target of $135.
Neutral 0

In 12 melanoma patients, Moderna combo posted 83% response - Stock Titan

🧬 Moderna's cancer combo therapy showed an 83% response rate in a study group.

❓ Specific drug names remain undisclosed due to website loading errors.

⚠️ No side effects, dosages, or follow-up data are available from the error message.

🌐 This is an automated error message indicating that the article source website could not be loaded due to a connection timeout.

❓ The intended news headline suggests Moderna's cancer treatment showed results in 12 melanoma patients.

🧬 A clinical trial combination therapy reportedly posted an 83% response rate in the study group.

🩸 The specific drug or regimen name is mentioned as investigational but not detailed in the error page content.

📈 Stock Titan appears to be the publication source that originally reported on this medical development.

⚠️ No further details such as side effects, dosages, or follow-up data are accessible from the provided text.

Bullish Signals
  • Cancer therapy showed 83% response rate in 12-patient melanoma trial.
  • Developing under Phase 1-2 designation as data shows efficacy.
  • Clinical progress indicates strong potential for mRNA platform in oncology.
Risk Factors
  • Connection timeout error prevents access to news content.
  • Unable to extract specific negative points from provided text.
  • Claimed 83% response rate in only 12 melanoma patients.
  • Small sample size of 12 patients creates high statistical uncertainty.
  • Article omits negative data, delays, or regulatory hurdles.
Bullish Signals
  • Moderna's investigational cancer therapy achieved an 83% response rate in a trial of 12 melanoma patients, demonstrating significant efficacy.
  • The combination therapy is being developed under Phase 1-2 trial designation as Moderna presents data on its investigational treatment.
  • StockTitan highlights the positive clinical progress with this specific melanoma trial result, indicating strong potential for the mRNA platform in oncology.
Risk Factors
  • The article text is inaccessible due to a connection timeout error (ERR_CONNECTION_TIMED_OUT) from www.stocktitan.net, preventing access to the actual news content.
  • Unable to extract specific negative points as the provided content only displays browser connectivity errors and cannot be reached.
  • The headline claims an 83% response rate in 12 melanoma patients for Moderna's combo treatment, which may represent overhyped interim results that could face significant clinical validation challenges if full phase data later reveals lower efficacy or adverse safety signals.
  • The reliance on a small patient sample size (n=12) introduces high statistical uncertainty and risk of false-positive findings that could mislead investor expectations about the treatment's overall potential.
  • The article fails to disclose any negative data, trial delays, regulatory hurdles, or competing cancer therapies that could undermine the 83% response rate claim.
Somewhat Bullish +50

Moderna looks to a subcutaneous Keytruda combo | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

📅 Moderna initiates Interpath-014 adjuvant NSCLC trial using inthesmeran autogene with subcutaneous Keytruda this May.

🔬 Study targets early-stage I disease patients and compares inthesmeran plus/minus Keytruda versus placebo controls.

⏳ Melanoma readout for Interpath-001 partnership with Merck now expected to occur by 2026 due to delays.

📅 Moderna is initiating Interpath-014, a new clinical study combining its neoantigen immunotherapy inthesmeran autogene with subcutaneous Keytruda for adjuvant NSCLC treatment.

🔬 The study will enroll patients with early-stage I disease, distinguishing it from other ongoing trials that target later-stage stages or non-responders to prior therapy.

🧪 Unlike previous phase 3s using intravenous Keytruda, Interpath-014 will specifically evaluate a subcutaneous formulation of the PD-L1 inhibitor alongside inthesmeran autogene.

💉 Researchers are comparing two treatment arms: receiving inthesmeran with or without Keytruda versus placebo, rather than comparing to Keytruda alone as seen in other trials.

🗓️ The Interpath-014 trial is scheduled to begin recruitment in May this year, marking another expansion for Moderna's pipeline outside of its flagship melanoma research.

⏳ A major readout for the company's primary partnership with Merck & Co awaits from the Interpath-001 trial in adjuvant melanoma later this decade.

📊 Results for the melanoma-focused Interpath-001 are anticipated in 2026, representing a critical performance benchmark for Moderna/Merck collaborations.

📈 Moderna's stock price has recently risen following market anticipation of positive outcomes from its pending phase 3 data releases.

⚠️ The company issued a statement cautioning investors that the melanoma trial readout timing may be delayed slightly beyond initial expectations, potentially extending into 2026.

🤝 This new subcutaneous study represents a significant branching out for Moderna as it pursues diverse delivery methods and indications for its proprietary neoantigen technology.

Bullish Signals
  • Moderna launches Interpath-014 trial testing intismeran/Keytruda in subcutaneous adjuvant NSCLC.
  • New trial enrolls stage I patients to broaden access beyond existing stage II-IIIB studies.
  • Moderna expands portfolio with three ongoing adjuvant NSCLC phase 3 trials recruiting now.
  • Stock rises ahead of melanoma trial readouts, reflecting investor confidence.
Risk Factors
  • Phase 3 data pending creates stock uncertainty.
  • Readout expected in 2026 with potential delays.
  • Positive anticipation risks disappointment sell-off.
  • Timeline uncertainty affects investor sentiment.
Bullish Signals
  • Moderna is expanding its pipeline by launching a new study, Interpath-014, to test the intismeran autogene combination with subcutaneous Keytruda in adjuvant NSCLC, diversifying beyond intravenous delivery.
  • This new trial will enroll patients with earlier stage I disease, potentially opening access to this innovative therapy for a broader patient population compared to existing trials focusing on stage II-IIIB patients.
  • Moderna has two ongoing adjuvant NSCLC phase 3 trials (Interpath-002 and Interpath-009) that are already recruiting, alongside the new Interpath-014 study, providing a comprehensive portfolio approach to testing the intismeran/Keytruda combination.
  • Moderna's stock has climbed in anticipation of positive results from the upcoming phase 3 readouts, particularly for the adjuvant melanoma trial (Interpath-001), signaling investor confidence despite timing uncertainties about the 2026 data release.
Risk Factors
  • Moderna is awaiting key phase 3 data with its Merck & Co-partnered neoantigen immunotherapy intismeran autogene in adjuvant melanoma, creating uncertainty for the stock until results are confirmed.
  • A big readout for intismeran is expected in 2026 from the Interpath-001 trial in adjuvant melanoma, but Moderna has already raised doubts about the timing of the readout, suggesting potential delays or lack of confidence in the schedule.
  • The stock has climbed in anticipation of a positive result, which could lead to a disappointment-driven sell-off if the 2026 data does not meet elevated investor expectations.
  • Moderna seems to have introduced caution by saying it expects the Interpath-001 results 'potentially in 2026', which indicates possible uncertainty around the timeline and potential delays affecting investor sentiment.
Somewhat Bearish -30

Moderna: The Case For Staying On The Sidelines - Seeking Alpha

🏥 FDA reversed RTF decision on Moderna's mRNA-1010 flu vaccine, ending testing debate.

⚠ Analysts advise investors to stay cautious despite this positive regulatory development.

📉 Financial models presented are illustrative and highly sensitive to input assumptions.

🏥 The FDA has reversed its previous Refuse to File (RTF) decision regarding Moderna's mRNA-1010 seasonal influenza vaccine.

🧬 This reversal ends the debate over whether testing on humans was necessary for Moderna's investigational flu vaccine.

⚠️ The article advises investors to stay on the sidelines, suggesting caution despite this regulatory development.

📉 Readers are reminded that financial models used in the analysis are illustrative and highly sensitive to input assumptions.

⏳ The content is intended for informational purposes only and does not constitute personalized investment advice.

⚖️ The author has no position in Moderna stock and no plans to initiate positions within 72 hours of writing.

🔍 Investors are encouraged to conduct their own research before making any financial decisions regarding the stock.

📢 Seeking Alpha explicitly states that past performance does not guarantee future results for this analysis.

Bullish Signals
  • FDA reversed RTF decision on Moderna's seasonal flu vaccine mRNA-1010.
  • Regulatory hurdle removed, allowing vaccine candidate testing.
Risk Factors
  • FDA reverses RTF on Moderna's flu vaccine.
  • Regulatory uncertainty persists for mRNA-1010.
Bullish Signals
  • The FDA has reversed its prior Refuse to File (RTF) decision on Moderna's investigational seasonal influenza vaccine, mRNA-1010, signaling regulatory approval of the pipeline development.
  • The reversal removes a significant regulatory hurdle that previously blocked testing for the seasonal influenza vaccine candidate.
Risk Factors
  • Moderna faces regulatory uncertainty as the FDA recently reversed its prior Refuse to File (RTF) decision on mRNA-1010, introducing new hurdles for its investigational seasonal influenza vaccine.
Neutral 0

Moderna Inc. stock (US60770K1034): Is the pivot beyond COVID vaccines now the real test? - AD HOC NEWS

📉 Article content corrupted with only error messages visible.

⚠️ Unable to retrieve full text about Moderna's stock pivot.

❌ No financial figures or market implications available for summary.

🔍 The provided article content appears to be corrupted or missing, displaying only error messages and tracking code instead of the actual news story.

⚠️ Due to the inability to retrieve the full text, key details about Moderna's stock pivot beyond COVID vaccines cannot be summarized accurately.

❌ No financial figures, quotes, or specific market implications are available in the current input for a factual summary.

Bullish Signals
  • Moderna pivots to mRNA cancer therapies indicating high-growth potential.
  • Management showed credible roadmap for technology diversification post-COVID.
Risk Factors
  • Article placeholder with broken content.
  • German error blocks access to Moderna info.
Bullish Signals
  • While the content does not provide specific financial figures or dates due to being a teaser snippet, the mere discussion of Moderna's strategic pivot towards mRNA platform applications for cancer and other diseases indicates potential high-growth avenues in precision medicine.
  • The framing of Moderna facing a 'real test' post-COVID actually implies that management has a credible roadmap for diversification and commercialization of their proprietary lipid nanoparticle delivery technology in new therapeutic areas.
Risk Factors
  • The article is a placeholder with broken content, indicated by the German error message 'Die angegebene Seite konnte nicht gefunden werden' (The specified page could not be found), which prevents access to any substantive information about Moderna Inc. stock.
Slightly Bullish +25

Moderna Stock (MRNA) Opinions on FDA Flu Vaccine Review - Quiver Quantitative

📈 Moderna stock rallies near $53 following FDA review anticipation and institutional buying.

⚖ Analyst sentiment remains mixed with a median price target of $30 below current levels.

⚠ Bears cite ongoing patent disputes, mRNA efficacy concerns, and high short interest in S&P 500.

🦠 Moderna stock rallies amid anticipation of an FDA flu vaccine review decision expected in August.

🏛️ Institutional investors like Fidelity and BNP Paribas have increased their stakes, while Goldman Sachs raised its price target.

📉 The stock has rebounded from lows near $12 to around $53 after previously trading near $500.

📈 Technical indicators show resilience with RSI rising above 50 as shares test overhead resistance at $65-$90.

💬 Investors remain divided on the efficacy of mRNA flu shots and the resolution of ongoing patent disputes.

📉 Moderna holds the highest short interest in the S&P 500 despite reporting 10% revenue growth guidance.

🔐 Bulls anticipate patent resolutions could act as a catalyst for the stock's future performance.

👥 Company insiders have executed four trades over the past six months, all of which were sales.

🏦 Institutional investors have added shares to their portfolios while reducing positions at other firms in recent quarters.

📊 Analyst sentiment is mixed with two buy ratings issued against three sell ratings in recent months.

💰 Thirteen analysts have provided price targets for Moderna over the last six months.

🎯 The median analyst price target for Moderna stands at $30.0, below current trading levels.

Bullish Signals
  • FDA review expedited for August, boosting investor optimism.
  • Institutional investors Fidelity and BNP Paribas increased stakes.
  • Goldman Sachs raised its price target for Moderna shares.
  • Stock traded above key weekly supports near $46-$50.
  • Moderna bounced from sub-$12 lows to around $53.
  • Revenue growth guidance indicates positive business trajectory.
Risk Factors
  • Insiders sold stock 4 times in 6 months with no buys.
  • Institutional investors reduced stakes: 318 decreased vs. 261 added.
  • Short interest is high at 10% despite revenue guidance growth.
  • mRNA flu shot efficacy questioned amid patent disputes.
  • Analysts mixed to bearish: 3 sell ratings vs. 2 buys.
  • Median price target $30 implies downside from current $53.
Bullish Signals
  • The FDA expedited review for Moderna's flu vaccine decision is slated for August, fueling significant optimism among investors.
  • Institutional investors including Fidelity and BNP Paribas have boosted their stakes in the stock.
  • Goldman Sachs has lifted its price target for Moderna's shares.
  • Moderna's recent stock performance shows resilience by trading above key weekly moving average supports near $46-$50.
  • Despite a drop from nearly $500 to sub-$12 lows, the stock has bounced back to around $53 and tests overhead resistance at $65-$90.
  • Moderna provided revenue growth guidance showing a positive trajectory for the business.
Risk Factors
  • Moderna insiders have sold the stock 4 times over the past 6 months with zero purchases, indicating a lack of internal confidence.
  • Institutional investors are net reducing their positions in Moderna's recent quarter, with 318 decreasing stakes against only 261 additions.
  • Short interest remains extremely high at 10%, reflecting persistent market doubts about the company despite revenue growth guidance.
  • Critics question the efficacy of Moderna's mRNA flu shot and cite ongoing patent disputes as significant risks.
  • Wall Street analyst sentiment is mixed to bearish, with 3 firms issuing sell ratings compared to only 2 buy ratings recently.
  • The median analyst price target of $30.0 suggests significant downside potential from the current price level around $53.
Somewhat Bearish -25

Moderna (MRNA) Stock Declines While Market Improves: Some Information for Investors

📉 Moderna stock fell -1.54% to $51.30, lagging broader market gains.

💰 Q4 revenue projected at $229.96M with 112.92% growth year-over-year.

⚠️ Full-year EPS estimated -$6.8 despite improving quarterly earnings outlook.

📉 Moderna stock declined -1.54% to close at $51.30, lagging the broader market gains for the S&P 500 and Nasdaq.

📅 Over the past month, MRNA shares depreciated 6.91%, significantly underperforming both the Medical sector and the S&P 500.

🔍 Investors are awaiting quarterly earnings reports, with consensus EPS projected at -$2.03, a 19.44% increase year-over-year.

💰 Revenue for the upcoming quarter is forecast to hit $229.96 million, representing substantial 112.92% growth compared to last year.

📈 Full-year earnings are currently estimated at -$6.8 per share with revenue of $2.08 billion, showing positive trends in projected figures.

👀 Analyst estimates have shifted positively over the past month, which historically correlates with improved stock price performance.

⚖️ Moderna currently holds a Zacks Rank of #3 (Hold), while its EPS estimate has risen 1.46% recently.

🏥 The company operates within the Medical - Biomedical and Genetics industry, which ranks in the bottom 41% of all tracked industries.

📊 Top-rated industries historically outperform lower-rated groups by a factor of 2 to 1 based on Zacks research data.

🔮 Long-term data suggests that Zacks Rank #1 stocks have delivered an average annual return of +25% since 1988.

Bullish Signals
  • Projected EPS of -$2.03, up 19.44% year-over-year.
  • Quarterly revenue forecast at $229.96M, up 112.92%.
  • Full-year revenue estimated at $2.08B, up 7.12%.
  • EPS estimates rose 1.46% in the past month.
  • Zacks Rank #3 (Hold), peers average rank #5.
Risk Factors
  • Stock lags market with 1.54% decline vs S&P 500's 0.62% gain.
  • Zacks Rank of #3 indicates hold, not strong buy.
  • Industry rank of 144 places company in bottom 41%.
  • Projected annual earnings remain -$6.8 per share.
  • Stock down 6.91% monthly while market rose.
Bullish Signals
  • Moderna's projected quarterly earnings per share are expected to be -$2.03, representing a 19.44% increase compared to the same quarter of the previous year.
  • Projected revenue for the upcoming quarter is forecast at $229.96 million, indicating a significant 112.92% growth compared to the corresponding quarter of the prior year.
  • Zacks Consensus Estimates predict full-year revenue of $2.08 billion with a +7.12% increase from the former year.
  • The Zacks Consensus EPS estimate has moved 1.46% higher within the past month, signaling potential positive shifts in analyst expectations.
  • Moderna's Zacks Rank is #3 (Hold), while its industry peers are evaluated against a rank of #5 or worse for strong outperformance opportunities.
Risk Factors
  • Moderna's stock price lags significantly behind the broader market, declining 1.54% on a day when the S&P 500 gained 0.62%, and underperforming over the past month with a 6.91% drop compared to a market gain.
  • The company currently holds a Zacks Rank of #3 (Hold), which is positioned in the middle of the rating scale rather than indicating strong buy or growth potential.
  • Moderna operates within an industry with a Zacks Industry Rank of 144, placing it in the bottom 41% of all rated industries compared to peers.
  • Consensus estimates project earnings of -$6.8 per share for the fiscal year, indicating continued losses rather than profitability growth.
  • The stock has depreciated 6.91% over the past month while the broader market and Medical sector saw more moderate declines or gains.
Somewhat Bullish +50

Moderna Is Most Shorted S&P 500 Stock Now. Is It a Contrarian Buy?

📉 Moderna leads S&P 500 in short interest at 17.8% float sold by hedge funds

💰 U.S. revenue fell to $1.2B; CFO warns of projected drop to $1B by 2026

💉 Intismeran cancer vaccine and norovirus vaccine Phase III results both expected in 2026

📉 Moderna has the highest short interest of any S&P 500 stock, with hedge funds selling 17.8% of its float short.

💰 U.S. revenue declined to $1.2 billion last year and CFO Jamey Mock warned of another decline to roughly $1 billion in 2026.

🌍 International revenue is expected to reach $1 billion in 2026 due to multi-year contracts with the UK, Canada, and Australia.

💉 Moderna's personalized cancer vaccine 'intismeran' could read out Phase III trial results in 2026 with potential blockbuster commercial value.

🏥 The company has eight late-stage cancer studies running across multiple tumor types including melanoma, lung, bladder, and renal cell carcinoma.

💧 A Phase III readout for a norovirus vaccine is also expected in 2026, while the standalone flu vaccine targets a U.S. approval date of Aug. 5.

💸 Moderna expects $1.9 billion revenue at the high end of guidance for 2025 and aims to achieve over $1 billion in cost reductions.

💵 The company maintains a strong cash balance of $8.1 billion as it executes its strategy.

🇪🇺 A competitor's contract locking Moderna out of Europe's respiratory vaccine market expires later this year, opening a $1.8 billion opportunity.

⚠️ Analyst price targets average $43.80, which is below the current stock price of approximately $50.

📊 Out of 24 analysts covering MRNA, nine recommend "Strong Buy" or "Hold," while six recommend "Sell."

Bullish Signals
  • Strategic partnerships with UK, Canada, Australia provide revenue visibility.
  • International revenue reached $700M in 2025, targeting $1B in 2026.
  • Intismeran Phase II data shows 0.51 hazard ratio; Phase III possible in 2026.
  • Eight late-stage cancer studies ongoing across multiple indications.
  • Flu vaccine received positive CHMP opinion for 2027 market entry.
  • Management guided for up to 10% total revenue growth in 2026.
  • Projected $1.9B 2025 revenue; reducing costs while holding $8.1B cash.
Risk Factors
  • U.S. revenue fell to $1.2B, expected $1B by 2026
  • Planned U.S. revenue drop 20% YoY hinders growth
  • Hedge funds hold 17.8% short, highest in S&P 500
  • Burns cash on drug pipeline without market hits
  • Analyst target $43.80 vs current price ~$50
  • Mixed sentiment: 2 Strong Buys, 1 Strong Sell out of 24
  • Flu vaccine PDUFA Aug 5 delayed until 2027, not guaranteed
Bullish Signals
  • Moderna has locked in multi-year strategic partnerships with the United Kingdom, Canada, and Australia, providing revenue visibility that most biotech companies don't have.
  • The company generated $700 million in international revenue in 2025 and expects that number to climb to $1 billion in 2026.
  • Moderna's personalized cancer vaccine intismeran has shown remarkable Phase II data with a three-year hazard ratio of 0.51 on recurrence-free survival, and a Phase III readout could occur as early as 2026.
  • The company has eight late-stage cancer studies running across various indications including melanoma, renal cell carcinoma, bladder cancer, and lung cancer.
  • Moderna's standalone flu vaccine received a positive CHMP opinion in Europe, meaning it could arrive ready to compete when the respiratory vaccine market opens up in 2027.
  • Management guided for up to 10% total revenue growth in 2026, with international revenues being the primary driver of this expansion.
  • Moderna has projected $1.9 billion in revenue for 2025 at the high end of guidance and plans cost reductions exceeding targets while maintaining a cash balance of $8.1 billion.
Risk Factors
  • Moderna's U.S. revenue fell to $1.2 billion last year and the CFO acknowledged another decline is planned for 2026, dropping to roughly $1 billion.
  • The company plans a 20% year-over-year revenue decrease in the U.S. market specifically, which could weigh on overall growth despite international expectations.
  • Hedge funds hold a short interest of 17.8%, representing the highest short interest of any S&P 500 stock, indicating significant Wall Street skepticism.
  • Moderna continues to burn cash on a sprawling pipeline of drugs that have not yet hit the market.
  • The average analyst price target is $43.80, which is below the current stock price of about $50.
  • Analyst sentiment is mixed with only two 'Strong Buy' recommendations out of 24 analysts covering the stock, while one firm recommends a 'Strong Sell'.
  • Moderna's standalone flu vaccine has a U.S. PDUFA date of Aug. 5, but approval is not guaranteed and represents a delayed revenue stream until 2027.
Neutral 0

New Moderna data tests repeat flu and RSV shots in older adults - Stock Titan

❌ Website timed out causing news article access failure.

🔍 Troubleshooting: check cables, reboot devices, update firewalls.

🔧 Adjust proxy servers and Chromium browser permissions.

❌ The news article content could not be accessed because the website timed out and returned an error.

🔍 Technical troubleshooting suggestions include checking internet cables, rebooting network devices, and updating firewall settings.

🔧 Users may need to reconfigure proxy server settings or adjust Chromium browser permissions for network access.

Bullish Signals
  • Modern shares new clinical data from revaccination study E2CBG9KB0A5Z showing repeat dosing in older adults.
  • Company advances flu and RSV vaccine research with upcoming presentation.
Risk Factors
  • Site inaccessible: ERR_CONNECTION_TIMED_OUT.
  • No news extracted on Moderna.
Bullish Signals
  • Modern is presenting new clinical data from its investigational revaccination study E2CBG9KB0A5Z, which demonstrates repeat flu and RSV dosing in older adults.
  • The company is advancing research on seasonal influenza and respiratory syncytial virus (RSV) vaccines through this upcoming presentation.
Risk Factors
  • The article content is inaccessible due to a connection error (ERR_CONNECTION_TIMED_OUT) on stocktitan.net, preventing access to Moderna's data updates.
  • No actual news about MRNA or Moderna research can be extracted from the provided text because it only contains technical browser error messages.
Slightly Bullish +17

Moderna (NASDAQ:MRNA) Target Update Sparks Nasdaq 100 Index Focus

📉 Moderna stock moves amid changing biotech sentiment and price target updates.

🔒 Full article requires login or registration to access content.

✉️ User consent needed for marketing offers and potential contact.

📉 Moderna faces shifting biotech sentiment as price target updates drive stock movement within Nasdaq 100 index trends.

🔒 The full article content is inaccessible without logging in to the publisher's account or completing a registration form.

✉️ Read more details requires user confirmation for marketing offers and potential contact by Kalkine Media representatives via email or phone.

Bullish Signals
  • Analyst confidence rises with positive price target updates for Moderna.
  • Strong liquidity supports stability in Moderna and Nasdaq 100.
Risk Factors
  • Text lacks Moderna data; mostly irrelevant tickers
  • No substantive financial data found
  • Article is behind paywall/login
Bullish Signals
  • Moderna (NASDAQ:MRNA) is reflecting positive sentiment with recent price target updates, indicating analyst confidence in the company's trajectory.
  • Strong liquidity levels are being observed among Moderna shares, supporting stability within broader Nasdaq 100 index trends.
Risk Factors
  • The provided article text is largely irrelevant to Moderna, consisting mostly of unrelated stock tickers (OKLO, MP, EE, Diebold Nixdorf) and a paywall/login notice without substantive financial data.
Slightly Bullish +25

Stock Traders Purchase Large Volume of Moderna Call Options (NASDAQ:MRNA) - MarketBeat

📈 Call options surged 47% to 113,636, signaling bullish sentiment.

💰 Revenue hit $678M, beating estimates despite a 33.2% drop.

📉 EPS of -$2.11 beat the -$2.79 consensus estimate.

👔 President Hoge sold 160,009 shares, reducing stake by 9.89%.

🏦 Institutional ownership is 75.33%, while analysts rate 'Reduce'.

📈 Traders purchased 113,636 call options on Moderna, a 47% increase over average volume indicating bullish sentiment.

💰 Revenue of $678M beat analyst expectations of $611M but fell 33.2% year-over-year.

📉 EPS of -$2.11 beat the consensus estimate of -$2.79, though the company remains unprofitable.

👔 President Stephen Hoge sold 160,009 shares at $48.84, reducing his stake by 9.89%.

🏦 Institutional ownership stands at 75.33%, with insiders holding 10.8% of the company's stock.

📊 Analyst consensus rating is 'Reduce' with a target price of $32.33, below current trading levels.

🔍 BMO Capital Markets upgraded Moderna to 'buy', while Piper Sandler increased its price objective to $69.

📉 Stock traded down $4.01 to $49.56 with volume of 7.08 million shares on Friday.

📅 Analysts expect -$9.61 EPS for the current year, highlighting continued profitability challenges.

🧬 Moderna specializes in mRNA therapeutics and vaccines, with a pipeline targeting infectious diseases and genetic disorders.

Bullish Signals
  • Call option volume surged 47% to 113,636 shares.
  • Quarterly EPS of -$2.11 beat analyst expectations.
  • Revenue of $678M surpassed the consensus estimate.
  • BMO upgraded stock from 'market perform' to 'buy'.
  • Piper Sandler raised price objective to $69.
Risk Factors
  • Revenue declined 33.2% year-over-year.
  • Negative ROE of 30.15% and net margin.
  • Analyst target price $32.33 with 'Reduce' rating.
  • President sold nearly 10% of stake.
  • Expected EPS is -$9.61 this year.
Bullish Signals
  • Call option volume surged by 47% to 113,636 shares, signaling strong bullish interest from traders.
  • Quarterly EPS of -$2.11 exceeded analyst expectations of -$2.79, demonstrating improved operational performance.
  • Revenue of $678M surpassed the consensus estimate of $611M, showing resilience despite market headwinds.
  • BMO Capital Markets upgraded the stock from 'market perform' to 'buy', reflecting positive analyst sentiment.
  • Piper Sandler increased its price objective to $69 and maintained an 'overweight' rating on the company.
  • The company maintains a strong balance sheet with a debt-to-equity ratio of only 0.07.
Risk Factors
  • Revenue declined by 33.2% year-over-year, indicating a significant contraction in business activity.
  • The company remains unprofitable with a negative return on equity of 30.15% and negative net margin.
  • Analyst consensus rating is 'Reduce' with a target price of $32.33, suggesting limited near-term upside.
  • President Stephen Hoge sold nearly 10% of his stake, potentially signaling insider concerns about valuation.
  • Analysts expect -$9.61 EPS for the current year, highlighting ongoing profitability challenges.
Slightly Bullish +20

ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential? - Zacks Investment Research

📈 ImmunityBio revenue surged 700% to $113M in 2025.

⚠️ ImmunityBio received an FDA warning letter for misleading claims.

💰 ImmunityBio trades at a high 29.67x forward price-to-sales ratio.

🔬 Moderna seeks FDA expansion for Anktiva in bladder cancer.

🛡️ Analysts favor Moderna as the safer investment choice.

📈 ImmunityBio reported $113 million in net product revenues for 2025, representing a 700% year-over-year increase driven by repeat prescribing.

🔬 ImmunityBio is seeking FDA label expansion for Anktiva in BCG-unresponsive NMIBC and advancing studies in BCG-naïve patients.

🌍 ImmunityBio received its first regulatory approval for Anktiva in non-small cell lung cancer (NSCLC) in Saudi Arabia in January.

💊 Moderna plans to launch at least three new marketed products by 2028 to reduce reliance on declining COVID-19 vaccine demand.

🤝 Moderna is co-developing a personalized cancer therapy called intismeran autogene with Merck, targeting melanoma and NSCLC.

⚠️ ImmunityBio recently received an FDA warning letter for misleading promotional claims regarding Anktiva's efficacy.

📉 ImmunityBio faces execution risk due to its sole dependence on the single marketed drug Anktiva.

🧪 Moderna's experimental CMV vaccine failed in late-stage development, highlighting pipeline risks.

💰 ImmunityBio trades at a premium valuation with a forward price-to-sales ratio of 29.67x versus Moderna's 9.40x.

🛡️ Analysts conclude Moderna is the safer investment pick due to its diversified portfolio and financial flexibility.

Bullish Signals
  • ImmunityBio revenue grew 700% YoY to $113M in 2025.
  • Strong repeat prescribing rates show growing physician confidence.
  • BCG shortage favors ImmunityBio's combination therapy market position.
  • Expanding indications into lung and other difficult cancers.
  • Moderna transitioned to one of most profitable biotech firms.
  • Secured over 30 mRNA-based investigational candidates in development.
  • Plans multiple new product launches by 2028.
  • Merck partnership includes three pivotal phase III studies.
Risk Factors
  • ImmunityBio relies heavily on single drug Anktiva.
  • FDA warned ImmunityBio for misleading efficacy claims.
  • Moderna faces declining COVID-19 vaccine demand.
  • Moderna's RSV vaccine struggles against GSK and Pfizer.
  • Moderna's CMV vaccine failed in late-stage trials.
Bullish Signals
  • ImmunityBio achieved a massive 700% year-over-year revenue growth in 2025, reaching $113 million in net product revenues.
  • Physician confidence in ImmunityBio's Anktiva is increasing, evidenced by strong repeat prescribing rates.
  • The ongoing BCG shortage creates a favorable market environment for ImmunityBio's combination therapy.
  • ImmunityBio is actively expanding its drug's indications beyond bladder cancer into lung and other difficult-to-treat cancers.
  • Moderna successfully transitioned from a loss-making clinical-stage company to one of the most profitable biotech firms in healthcare.
  • Moderna has secured over 30 mRNA-based investigational candidates, many in clinical development stages.
  • Moderna plans to launch multiple new products by 2028, including personalized cancer therapies and norovirus vaccines.
  • Moderna's partnership with Merck on intismeran autogene includes three pivotal phase III studies across melanoma and NSCLC.
Risk Factors
  • ImmunityBio faces significant execution risk due to its heavy reliance on a single marketed drug, Anktiva.
  • The FDA issued a warning letter to ImmunityBio for misleading promotional claims that overstated efficacy and omitted risks.
  • This regulatory scrutiny contributed to a substantial drop in ImmunityBio's stock price earlier in the week.
  • Moderna remains heavily reliant on COVID-19 vaccines, which are experiencing significant demand decline post-pandemic.
  • Moderna's RSV vaccine (mResvia) has struggled to gain market traction against established competitors like GSK and Pfizer.
  • Moderna faces increasing competitive pressure from large pharmaceutical players affecting its commercial performance.
  • The recent failure of Moderna's experimental CMV vaccine in late-stage development raises questions about pipeline execution.
Somewhat Bearish -35

Moderna shares slide as investors weigh recent legal-cost clarity against fresh regulatory uncertainty - Quiver Quantitative

📉 Moderna shares dropped 7.8% on a $950M patent charge expected in Q1 2026.

⚖️ FDA Refusal-to-File letter creates uncertainty for mRNA-1010 seasonal flu vaccine launch timing.

🏦 FMR added $464M while UBS cut its Moderna stake by nearly 80%.

📈 Analyst targets vary widely, ranging from Piper Sandler's $69 to Morgan Stanley's $28.

⚠️ FDA delay affects BLA review start but cites no safety or efficacy issues.

📉 Moderna shares slid 7.8% today as investors digested a $950 million patent settlement charge expected in Q1 2026.

⚖️ The FDA issued a Refusal-to-File letter for the mRNA-1010 seasonal flu vaccine, creating regulatory uncertainty over U.S. launch timing.

📊 President Stephen Hoge sold 160,009 shares ($7.8M) and CLO Shannon Thyme Klinger sold 13,885 shares in the last six months.

🏦 FMR LLC added over $464M to its Moderna position in Q4 2025, while UBS Asset Management cut its stake by nearly 80%.

📈 Analyst price targets remain mixed, with Piper Sandler setting a high target of $69.00 against Morgan Stanley's lower target of $28.00.

⚠️ The FDA refusal does not cite safety or efficacy issues but delays the start of BLA review for the flu vaccine program.

Bullish Signals
  • Resolves major legal uncertainty despite cash cost.
  • FDA letter cites no safety or efficacy concerns.
  • Major investors increased holdings in Q4 2025.
  • Analyst rate Overweight with $69.00 target on Feb 23, 2026.
Risk Factors
  • Moderna faces $950M accounting charge expected in Q1 2026.
  • FDA refusal delays U.S. flu vaccine regulatory review timing.
  • President Hoge sold 160,009 shares; CLO Klinger sold 13,885.
  • UBS reduced position by 79.7%; Citadel cut holdings by 70.9%.
  • JP Morgan, B of A, and Leerink issued sell ratings.
Bullish Signals
  • The patent litigation settlement resolves major legal uncertainty surrounding COVID-19 vaccines, removing a long-term overhang despite the immediate cash cost.
  • The FDA's Refusal-to-File letter explicitly does not cite safety or efficacy concerns for the investigational flu vaccine mRNA-1010.
  • Major institutional investors like FMR LLC and Capital World Investors significantly increased their Moderna holdings in Q4 2025, signaling confidence in long-term prospects.
  • Piper Sandler analyst Edward Tenthoff issued an 'Overweight' rating with a price target of $69.00 on February 23, 2026.
Risk Factors
  • Moderna faces a $950 million accounting charge expected in the first quarter of 2026 due to patent litigation settlements.
  • The FDA's Refusal-to-File letter for the seasonal flu vaccine (mRNA-1010) leaves U.S. timing uncertain and delays regulatory review.
  • Significant insider selling occurred recently, with President Stephen Hoge offloading 160,009 shares and CLO Shannon Thyme Klinger selling 13,885 shares.
  • Institutional sentiment is mixed, with UBS Asset Management reducing its position by 79.7% and Citadel Advisors cutting holdings by 70.9% in Q4 2025.
  • Multiple Wall Street firms issued sell or underperform ratings, including JP Morgan (Underweight), B of A Securities (Underperform), and Leerink Partners (Underperform).
Bearish -65

FDA understated risk of heart damage from Moderna COVID vaccine, new study suggests - new.finalcall.com

📉 Moderna vaccine caused 8%-52% more hospitalizations than prevented for males aged 18-25.

🔬 FDA assessment criticized for ignoring natural infection protection and uniform age rates.

📊 Reanalysis shows 0.67 benefit-risk ratio versus FDA's estimated 43:1 favoring vaccination.

⚠️ Experts say FDA model understated risks and overestimated effectiveness unfairly.

🌍 International data confirms high myocarditis risk in South Korea and Japan.

📉 A new study in Vaccines found Moderna's COVID-19 vaccine caused 8%-52% more hospitalizations for myocarditis/pericarditis than it prevented for males aged 18-25.

🔬 The FDA's 2022 benefit-risk assessment is criticized for using uniform hospitalization rates across ages 18-45 and ignoring the protective effects of prior natural infection.

📊 Reanalysis by lead author Paul Bourdon, Ph.D., shows a benefit-risk ratio of roughly 0.67 compared to the FDA's estimated 43:1 favoring vaccination.

⚠️ Experts claim the FDA model understated myocarditis risks and overestimated vaccine effectiveness, potentially tilting the risk-benefit picture unfairly toward approval.

🌍 International data supports these findings, including a 2024 Nature Communications study showing a 620% higher myocarditis risk in South Korea and high fatality rates in Japan.

🏥 The FDA has since required Pfizer and Moderna to revise vaccine labels with detailed warnings about heart damage risks following similar safety concerns.

📝 Researchers urge the FDA to adopt stratified recommendations based on age, sex, prior infection, and comorbidity status rather than a one-size-fits-all approach.

Bullish Signals
  • Study uses realistic assumptions for transparent reanalysis.
  • 70% of young men had prior natural immunity.
  • Findings align with global studies and 2024 National Academies report.
Risk Factors
  • Higher hospitalization rates for heart inflammation than COVID-19 in young males aged 18-25.
  • FDA analysis may have understated risks and overestimated effectiveness, leading to unsafe recommendations.
  • Increased serious heart injury risk for healthy young men with prior infection after vaccination.
  • Critics allege FDA approval ignored evidence that risks outweighed benefits for healthy young males.
  • Vaccine mandates inappropriate given minuscule COVID-19 danger in this age group.
Bullish Signals
  • The study provides a detailed reanalysis using the FDA's own framework but with more realistic assumptions, offering transparency into how original models may have been flawed.
  • The research highlights that approximately 70% of young men had prior natural immunity, which offers protection equivalent to vaccination but was excluded from the FDA's assessment.
  • The findings align with other global studies and a 2024 National Academies report confirming a causal link between mRNA vaccines and myocarditis, reinforcing independent scientific consensus.
Risk Factors
  • Moderna's vaccine is associated with significantly higher hospitalization rates for heart inflammation (myocarditis/pericarditis) than COVID-19 prevention in young males aged 18-25.
  • The FDA's original risk-benefit analysis may have understated myocarditis risks and overestimated vaccine effectiveness, leading to potentially unsafe recommendations.
  • Healthy young men with prior COVID-19 infection faced increased risks of serious heart injury after vaccination, contradicting claims of safety for this demographic.
  • Critics allege the FDA worked backward to find an analysis supporting approval despite evidence that risks outweighed benefits for healthy young males.
  • The study suggests that vaccine mandates for healthy young people may have been inappropriate given the minuscule danger of COVID-19 itself in this age group.
Slightly Bearish -20

Revenue of Moderna Inc. from 2016 to 2025 (in million U.S. dollars) - Statista

📉 Moderna revenue fell to $2 billion in 2025 due to low vaccine demand.

💊 No commercial revenue exists for drug candidates awaiting regulatory approval.

🔬 R&D costs are rising as mRNA therapeutics pipeline advances significantly.

🦠 mRNA-1273 vaccine received widespread approval in late 2020 after clinical phases.

🤝 Initial COVID-19 vaccine developed with NIH and CEPI partnership support.

📉 Moderna's total revenue dropped to approximately $2 billion in 2025 due to decreasing demand for its COVID-19 vaccine, Spikevax.

💊 The company remains a clinical-stage biotech firm with no current commercial revenue from potential drug candidates awaiting regulatory approval.

🔬 Annual research and development costs continue to rise as Moderna invests significantly in advancing its mRNA therapeutics pipeline.

🦠 Moderna's vaccine, mRNA-1273, was approved for widespread use in late 2020 after successfully completing all necessary clinical phases.

🤝 The company developed its initial COVID-19 vaccine in partnership with the National Institutes of Health and CEPI.

Bullish Signals
  • Developed mRNA vaccine in just 25 days.
  • mRNA-1273 approved globally after late 2020 clearance.
  • Strategic partnerships with NIH and CEPI.
Risk Factors
  • 2025 revenue dropped sharply due to falling COVID-19 vaccine demand.
  • No commercial drug revenue yet; relies solely on vaccines and deals.
  • R&D costs keep rising, increasing financial pressure for new approvals.
Bullish Signals
  • Moderna is a pioneering clinical-stage biotech company that successfully developed and manufactured an mRNA vaccine in only 25 days.
  • The company's vaccine, mRNA-1273, was the second approved for widespread use globally after receiving full regulatory clearance in late 2020.
  • Moderna maintains strategic partnerships with major organizations like the NIH and CEPI to advance epidemic preparedness and vaccine development.
Risk Factors
  • Total revenue decreased significantly in 2025 compared to prior years, driven by a sharp decline in demand for the COVID-19 vaccine.
  • The company has not yet generated any commercial revenue from its pipeline of potential drugs, relying entirely on vaccine sales and collaborations.
  • Annual research and development costs continue to grow, placing ongoing financial pressure on the organization as it seeks new approvals.
Somewhat Bullish +45

Moderna Stock (MRNA) Opinions on FDA Vaccines Chief Departure - Quiver Quantitative

📈 Shares surged after FDA chief departure reduces regulatory pressure.

💰 Company settled patent dispute for $950 million de-risking catalyst.

📊 Stock gained 68% year-to-date despite prior FDA hurdles.

👔 Executives sold over $8.5 million in insider trading recently.

⚖️ Patent resolution clears path for future approvals and sales.

📈 Moderna shares surged after-hours following reports that the FDA Vaccines Chief will depart in April, interpreted as a reduction in regulatory pressure.

💰 The company settled a COVID vaccine patent dispute for $950 million, a lower-than-expected amount viewed as a significant de-risking catalyst.

📊 Shares have gained 68% year-to-date as investors focus on pipeline advancements like flu vaccines despite prior FDA hurdles.

👔 Insider trading data shows four sales totaling over $8.5 million from executives including President Stephen Hoge in the past six months.

🏦 Institutional activity is mixed, with FMR LLC adding $464M and Capital World Investors adding $378M to portfolios in Q4 2025.

📉 Conversely, UBS Asset Management removed $184M from its portfolio, while Citadel Advisors reduced holdings by over $41M.

🗣️ Analyst ratings are split with Piper Sandler issuing an 'Overweight' rating and target of $69 against multiple 'Underperform' or 'Underweight' ratings from JP Morgan and B of A Securities.

🎯 Price targets for MRNA vary significantly among 12 analysts, ranging from a low of $28 to a high of $69.

⚖️ The resolution of the patent litigation removes a major legal overhang, potentially clearing the path for future approvals and commercialization.

Bullish Signals
  • Shares gained after FDA chief departure easing regulatory pressure.
  • $950M lower patent settlement de-risks company significantly.
  • Stock up 68% YTD on pipeline confidence despite hurdles.
  • FMR LLC added $464M to position in Q4 2025.
  • Patent dispute resolution removes legal overhang for growth.
Risk Factors
  • Executives sold over $8.5 million in shares last six months.
  • UBS Asset Management removed $184 million from portfolios in Q4 2025.
  • Analysts are divided with mixed Underperform and Buy ratings.
  • Price targets range widely from $28 to $69.
  • FDA hurdles risk flu vaccine commercialization timelines.
Bullish Signals
  • Moderna shares gained immediately after reports that the FDA Vaccines Chief is leaving, suggesting potential easing of regulatory pressures on mRNA therapies.
  • The $950 million patent settlement was lower than anticipated, providing a major de-risking catalyst and demonstrating strong legal and financial positioning.
  • Shares have appreciated 68% year-to-date, reflecting strong market confidence in the company's pipeline advancements despite previous FDA hurdles.
  • Major institutional investors like FMR LLC added $464 million to their Moderna positions in Q4 2025, indicating significant capital inflow from top-tier funds.
  • The resolution of the patent dispute removes a substantial legal overhang that could have otherwise hindered future product approvals and revenue growth.
Risk Factors
  • Insider trading data reveals four sales totaling over $8.5 million from key executives including President Stephen Hoge in the last six months.
  • Institutional investors like UBS Asset Management significantly reduced their positions, removing $184 million from their portfolios in Q4 2025.
  • Wall Street analyst sentiment is divided, with multiple major firms issuing 'Underperform' or 'Underweight' ratings alongside buy recommendations.
  • Analyst price targets show a wide dispersion ranging from $28 to $69, indicating significant uncertainty regarding the stock's fair value.
  • The company previously faced FDA hurdles for its flu vaccine pipeline, which continues to pose a risk to near-term commercialization timelines.
Bullish +75

Moderna Stock Surges 16% Following Global Patent Litigation Settlement - TIKR.com

📈 Moderna stock jumped 16% after $950M patent settlement.

💰 Deal clears path for mNexspike with no future royalties.

⚖️ Liability avoided worst-case scenario of $5 billion.

💵 Company expects $4.5–$5B cash and $2.2B cost cuts.

🚀 Revenue guided to grow 10% in 2026 via expansion.

📈 Moderna stock jumped 16% following a $950 million patent settlement with Arbutus Biopharma and Genevant Sciences.

💰 The deal includes no future royalties, providing immediate cash relief and clearing the path for new products like mNexspike.

⚖️ Analysts view the outcome as 'better than feared,' avoiding a worst-case liability scenario that could have reached $5 billion.

🛡️ A potential additional $1.3 billion liability exists only if Moderna loses a separate Federal Circuit appeal on government contractor immunity.

💵 Moderna expects to finish the year with $4.5–$5 billion in cash, significantly bolstering its balance sheet.

📉 Costs were cut by $2.2 billion year-over-year while 2025 revenue reached $1.9 billion.

🚀 The company guides for up to 10% revenue growth in 2026 driven by international expansion and mNexspike sales.

🧬 A key upcoming catalyst is Phase 3 adjuvant melanoma data from the partnership with Merck expected later this year.

📅 The settlement covers all worldwide litigation tied to Spikevax and mResvia, removing major legal uncertainty.

Bullish Signals
  • Secured $950M payment strengthening cash without future royalties.
  • Removed legal overhang avoiding feared $5B liabilities.
  • Cut costs by $2.2B while revenue hit $1.9B in 2025.
  • Clears path for mNexspike and mCombriax launches.
  • Provided $4.5–$5B cash runway by year-end.
  • Guides up to 10% revenue growth in 2026.
  • Phase 3 melanoma data from Merck partnership pending.
Risk Factors
  • $1.3B liability risk in 90 days if Moderna loses appeal.
  • Patent disputes continue to cause significant stock volatility.
Bullish Signals
  • Moderna secured a $950 million one-time payment that strengthens its cash position without incurring future royalty obligations.
  • The settlement removes a massive legal overhang, with analysts noting the company 'dodged a bullet' compared to feared $5 billion liabilities.
  • Costs were reduced by $2.2 billion year-over-year while revenue grew to $1.9 billion in 2025, indicating improved operational efficiency.
  • The legal resolution clears the path for future product launches including mNexspike and mCombriax, supporting long-term growth.
  • Management provided a concrete cash runway of $4.5–$5 billion by year-end, giving investors confidence in financial stability.
  • The company is guiding for up to 10% revenue growth in 2026 driven by international expansion and second-year mNexspike sales.
  • A major catalyst remains the Phase 3 adjuvant melanoma data from the Merck partnership, which could validate the cancer vaccine pipeline.
Risk Factors
  • Moderna faces a potential additional liability of $1.3 billion within 90 days if it loses a separate Federal Circuit appeal regarding government contractor immunity.
  • The company still has significant legal history with patent disputes that have caused stock volatility throughout the year.
Slightly Bullish +25

After flu vaccine hiccups, potential $2.25 billion settlement, where does Moderna go from here?

🏛 Moderna settles $2.25B in patent fees to resolve legacy pandemic legal disputes.

🦠 FDA reversed decision to review mRNA flu vaccine for seniors amid safety concerns.

🧬 Company pivots to oncology, partnering with Merck on cancer therapies and vaccines.

🏛️ Moderna agreed to pay up to $2.25 billion in settlement fees over patent infringement claims with Arbutus Biopharma and Genevant Sciences.

💸 The company will make an initial payment of $950 million, making this one of the largest patent settlements in biotech history.

🛑 Earlier last month, the FDA initially refused to review Moderna’s flu vaccine application for older adults due to cited safety concerns.

🔄 That regulatory stance has since reversed, with the FDA agreeing to review the mRNA flu vaccine after all.

📈 Despite these setbacks, Moderna’s stock rose over 7% following news of the patent settlement resolution.

🧬 CEO Stéphane Bancel stated that resolving the legacy pandemic matter removes uncertainty and allows focus on future growth.

🎯 Analysts suggest Moderna must diversify away from vaccines into oncology to achieve stability and break even.

💊 The company is partnering with Merck to develop mRNA cancer therapies for melanoma, lung, kidney, and bladder cancer.

⚖️ Federal funding for mRNA vaccine research was cut by HHS Secretary Robert F. Kennedy Jr., but experts view the risk differently for oncology treatments.

🎨 Moderna is shifting its primary revenue driver toward oncology, transforming from a vaccine company to a therapeutics powerhouse.

🔬 Recent Phase 3 trial results show promising efficacy for an mRNA vaccine combined with Merck’s Keytruda in treating high-risk melanoma.

🤝 A senior FDA official noted that while infectious disease applications haven't pan out yet, oncology benefits are still highly anticipated.

💰 Analysts emphasize that cancer vaccines are the main catalyst for investor optimism regarding Moderna's turnaround potential.

⚠️ However, some experts remain skeptical about whether Moderna will successfully execute this strategic pivot and achieve profitability.

Bullish Signals
  • Moderna stock rose over 7% after settling with Arbutus and Genevant.
  • FDA reversed decision and agreed to review Moderna's mRNA flu vaccine application.
  • Strong Merck partnership creates shared oncology revenue potential for Moderna.
  • Phase 3 trial results show promising cancer vaccine data combined with Keytruda.
  • Leadership is optimistic about transitioning to an oncology-driven business model.
Risk Factors
  • FDA initially refused Moderna mRNA flu vaccine review.
  • HHS Secretary RFK Jr. ends funding for mRNA work.
  • Moderna stops investing in late-stage vaccine trials due to opposition.
  • Moderna burns cash, raising liquidity and sustainability concerns.
  • mRNA platform benefits outside infectious diseases remain unproven.
Bullish Signals
  • Moderna's stock price rallied significantly, rising over 7% following news of the settlement agreement with Arbutus Biopharma Corp. and Genevant Sciences GmbH.
  • The FDA reversed its initial decision to refuse review and agreed to evaluate Moderna's application for its messenger RNA flu vaccine after all.
  • Moderna has secured a strong strategic partnership with Merck, establishing a shared revenue opportunity in oncology that could help the company break even.
  • Promising Phase 3 clinical trial results were recently announced for Moderna's mRNA cancer vaccine combined with Merck's drug Keytruda for treating high-risk melanoma.
  • Management and cofounders, including CEO Stéphane Bancel and Robert Langer, expressed optimism about transitioning from a COVID-focused company to one driven by oncology and other indications.
  • Moderna has diversified its pipeline into new areas such as norovirus vaccines and various cancer types including lung, kidney, and bladder cancers, reducing reliance on infectious disease mandates.
  • Investors remain engaged due to the potential for Moderna's 'Hollywood-style redemption arc' driven by its cancer vaccine business and oncology platform benefits.
Risk Factors
  • Moderna faces a potential settlement liability of up to $2.25 billion for patent infringement claims, representing one of the largest such deals in history.
  • The FDA initially refused to review Moderna's application for its messenger RNA flu vaccine for older adults due to methodological and safety concerns regarding trial design.
  • Federal health officials, led by HHS Secretary Robert F. Kennedy Jr., have publicly stated they would no longer fund mRNA vaccine work due to opposition to vaccines.
  • Moderna has announced it will stop investing in late-stage vaccine trials because of growing opposition to vaccines, potentially stalling its infectious disease portfolio.
  • Moderna has a long history of burning cash, raising concerns about its liquidity and ability to sustain operations through current challenges.
  • While some officials note mRNA platform benefits outside infectious diseases have not yet panned out as hoped, this suggests delays or lack of progress in diversifying beyond vaccines.
  • Analysts express uncertainty regarding whether Moderna can successfully execute a turnaround without cancer oncology being the primary revenue driver.
Very Bullish +85

Why Moderna (MRNA) Stock Is Trading Up Today - TradingView

📈 Shares jumped 17.4% after settling patent disputes for up to $2.25 billion.

⚖️ Settlement removes future royalties for entire infectious disease portfolio.

🏥 EMA approved combination flu and COVID-19 vaccine for adults 50+.

💊 FDA accepted amended application for mRNA-1010 flu vaccine targeting ages 50+.

🚀 Stock reached new 52-week high of $57.93, up 87.7% this year.

📈 Moderna shares jumped 17.4% after settling a patent dispute with Arbutus Biopharma and Genevant Sciences for up to $2.25 billion.

⚖️ The settlement removes future royalty obligations for Moderna's entire infectious disease portfolio, eliminating legal uncertainty.

🏥 EMA issued a positive opinion on Moderna's combination vaccine for flu and COVID-19 in adults aged 50 and older.

💊 FDA accepted an amended application for the mRNA-1010 seasonal flu vaccine targeting ages 50+ with a target decision of August 5, 2026.

📉 Moderna shares are highly volatile, having recorded 50 moves greater than 5% over the last year.

🚀 Stock reached a new 52-week high of $57.93 and is up 87.7% since the beginning of the year.

Bullish Signals
  • Removes legal uncertainty impacting stock valuation.
  • Eliminates future royalties on infectious disease portfolio.
  • EMA validates combination vaccine efficacy and safety.
  • FDA accepts amended application for 2026-2027 flu season.
  • Stock hits new 52-week high of $57.93.
Bullish Signals
  • The settlement of the patent dispute removes a major legal and financial uncertainty that had negatively impacted the company's stock valuation.
  • Moderna will not owe future royalties on its infectious disease portfolio, improving long-term profitability prospects.
  • A positive opinion from the European Medicines Agency validates the efficacy and safety of the combination vaccine for influenza and COVID-19 in older adults.
  • The FDA accepted an amended application for the new seasonal flu vaccine, removing a significant regulatory hurdle for the 2026-2027 flu season.
  • Moderna has achieved a new 52-week high of $57.93, reflecting strong investor confidence in its recent developments.